SIM2 and OR51E2-prostate cancer development and progression,target for immunotherapy,better diagnosis than PSA test when combined with miR-200c and miR-200b,cancer diagnosis with PSA≤4 ng/mLmiR-200c-bone metastasis,PSA level > 10 ng/μL,Bilateral tumor. This evidence concerns the gene OR51E2 and prostate carcinoma.